The FDA Should Listen to Its Own Evidence on Surrogate Markers
Dr Gyawali explores the limited evidence to justify FDA drug approvals based on surrogate markers.
Dr Gyawali explores the limited evidence to justify FDA drug approvals based on surrogate markers.
British Journal of Cancer – UK guidelines for the management of soft tissue sarcomas
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine-…
We characterize the genetic diversity of Nipah viruses across South and Southeast Asia and find substantial diversity, with multiple lineages circulating w
I remember a consultation with a patient of mine. They had just had an operation. The surgeon had told them that they would need three…
Click on the article title to read more.
It’s a valid question, but their efficacy isn’t the focus here. A major pharmacy chain in Sweden has introduced age restrictions for the purchase of…
This is not a repeat of the Covid pandemic. Yet global governments should follow the US and prepare a response, writes global public health expert…
The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of…
In a pair of Special Reports, Gökbuget and colleagues present updated European Leukemia Net (ELN) consensus reports on (1) the diagnosis, prognostic factor